RPS6KB1 and glioblastoma: Recognizing that U87MG cells are not necessarily a high-fidelity model of GBM because of long passage time and issues related to identification of the tumor of origin, these results are suggestive of the therapeutic potential of combination inhibition of S6K1 and AXL (43).